Sumitomo Dainippon Pharma Co Ltd (4506.T)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2017||Senior Managing Executive Officer, Representative Director|
|60||2016||Managing Executive Officer, Chief Director of Sales, Director|
|2017||Managing Executive Officer, Chief Director of Production|
|2017||Managing Executive Officer|
|2017||Managing Executive Officer, Chairman & Chief Executive Officer of Subsidiary|
- BRIEF-Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan
- BRIEF-Sumitomo Dainippon Pharma says result of early-retirement program
- BRIEF-Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
- BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
- BRIEF-Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin